Drug discovery: lessons from evolution
- PMID: 21395642
- PMCID: PMC3080636
- DOI: 10.1111/j.1365-2125.2010.03854.x
Drug discovery: lessons from evolution
Abstract
A common view within the pharmaceutical industry is that there is a problem with drug discovery and we should do something about it. There is much sympathy for this from academics, regulators and politicians. In this article I propose that lessons learnt from evolution help identify those factors that favour successful drug discovery. This personal view is influenced by a decade spent reviewing drug development programmes submitted for European regulatory approval. During the prolonged gestation of a new medicine few candidate molecules survive. This process of elimination of many variants and the survival of so few has much in common with evolution, an analogy that encourages discussion of the forces that favour, and those that hinder, successful drug discovery. Imagining a world without vaccines, anaesthetics, contraception and anti-infectives reveals how medicines revolutionized humanity. How to manipulate conditions that favour such discoveries is worth consideration.
© 2011 The Author. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
Similar articles
-
Challenges and opportunities in bringing new medications to market for pediatric patients.J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1056-1059. doi: 10.1097/CHI.0b013e3181baec67. J Am Acad Child Adolesc Psychiatry. 2009. PMID: 19855220 No abstract available.
-
Bilski blundering biotech.Nat Biotechnol. 2009 Mar;27(3):245-8. doi: 10.1038/nbt0309-245. Nat Biotechnol. 2009. PMID: 19270670 No abstract available.
-
Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.Clin Pharmacol Ther. 2013 Jun;93(6):515-25. doi: 10.1038/clpt.2013.32. Epub 2013 Feb 12. Clin Pharmacol Ther. 2013. PMID: 23571772
-
Considerations in the early development of biosimilar products.Drug Discov Today. 2015 May;20 Suppl 2:1-9. doi: 10.1016/j.drudis.2014.12.017. Epub 2015 Jan 6. Drug Discov Today. 2015. PMID: 25572407 Review.
-
Examining Manufacturing Readiness for Breakthrough Drug Development.AAPS PharmSciTech. 2016 Jun;17(3):529-38. doi: 10.1208/s12249-015-0455-1. Epub 2015 Nov 25. AAPS PharmSciTech. 2016. PMID: 26608693 Review. No abstract available.
Cited by
-
Antibacterial sensitizers from natural plants: A powerful weapon against methicillin-resistant Staphylococcus aureus.Front Pharmacol. 2023 Feb 24;14:1118793. doi: 10.3389/fphar.2023.1118793. eCollection 2023. Front Pharmacol. 2023. PMID: 36909155 Free PMC article. Review.
-
Population Modelling in Affective Disorders.Curr Behav Neurosci Rep. 2021;8(2):21-27. doi: 10.1007/s40473-021-00229-6. Epub 2021 Apr 15. Curr Behav Neurosci Rep. 2021. PMID: 33875934 Free PMC article. Review.
-
The Role of Norrish Type-I Chemistry in Photoactive Drugs: An ab initio Study of a Cyclopropenone-Enediyne Drug Precursor.Front Chem. 2020 Dec 22;8:596590. doi: 10.3389/fchem.2020.596590. eCollection 2020. Front Chem. 2020. PMID: 33425854 Free PMC article.
References
-
- Rosen W. The Most Powerful Idea in the World. A Story of Steam, Industry and Invention. London: Jonathan Cape; 2010. p. 108. 324.
-
- Hughes B. 2009 FDA drug approvals. Nat Rev Drug Discov. 2010;9:89–92. - PubMed
-
- Drake JM, Griffen BD. Early warning signals of extinction in deteriorating environments. Nature. 2010;467:456–9. - PubMed
-
- Eichler H-G, Aronsson B, Abadie E, Salmonson T. New drug approval success rate in Europe in 2009. Nat Rev Drug Discov. 2010;9:355–6. - PubMed
-
- Van Valen L. A new evolutionary law. Evol Theory. 1973;1:1–30.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources